T cell therapy for ALL
T cell therapy for ALL
The ACE-LY-004 study of acalabrutinib monotherapy for mantle cell lymphoma
Neuroblastoma and cell communication networks
Shortening the time to manufacture CAR T-cells
Anti-BCMA CAR T cell therapy for multiple myeloma
Data from the CLARITY trial of ibrutinib plus venetoclax
Mogamulizumab for cutaneous T- cell lymphoma
Phase 1 study of Blu-285 in advanced systemic mastocytosis
Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma